-body irradiation or radioimmunotherapy) given before autologous stem cell transplantation, may also increase the risk of therapy-related MDS/AML. 12 , 13 NCCN Clinical Practice Guidelines in Oncology : Acute Myeloid Leukemia, Version 2.2012 Version 2
Search Results
Acute Myeloid Leukemia
Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Daniel A. Arber, Eyal Attar, Uma Borate, Steven E. Coutre, Lloyd E. Damon, Salil Goorha, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, Eunice S. Wang, Maoko Naganuma, and Kristina M. Gregory
Acute Myeloid Leukemia
Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman, and Eunice S. Wang
Overview I n 2010, approximately 12,330 people were diagnosed with and 8950 died of acute myeloid leukemia (AML). 1 As the population ages, the incidence of AML, along with myelodysplasia, seems to be rising. Equally disturbing is the
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret R. O'Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Vijaya Bhatt, Dale Bixby, William Blum, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Steven D. Gore, Aric C. Hall, Patricia Kropf, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Joseph O. Moore, Rebecca Olin, Deniz Peker, Daniel A. Pollyea, Keith Pratz, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Matthew Wieduwilt, Kristina Gregory, and Ndiya Ogba
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults, and it
Risk Stratification and Emerging Treatment Strategies in Acute Myeloid Leukemia
Margaret R. O’Donnell
Bone Marrow Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, and Chair of the Acute Myeloid Leukemia (AML) Panel of NCCN. Thus, the changes in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML
Allogeneic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Myeloid Leukemia
Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage
+ -AML Identify the evidence supporting clinicopathologic distinction between Ph + -AML and chronic blast phase CML Discuss the role of SCT in the treatment of Ph + -AML Philadelphia chromosome-positive acute myeloid leukemia (Ph
Acute Myeloid Leukemia, Version 2.2013
Margaret R. O’Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Eyal Attar, Uma Borate, Steven E. Coutre, Lloyd E. Damon, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Kristina M. Gregory, and Maoko Naganuma
otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. NCCN Guidelines Insights : Acute Myeloid Leukemia, Version 2
Advances in Acute Myeloid Leukemia Management: Focus on Secondary Disease and Older Patients
Presented by: Daniel A. Pollyea
After several stagnant decades, the tides have shifted for the field of acute myeloid leukemia (AML). In the past several years, multiple new therapies have been approved, leaving AML providers with a multitude of new therapies. These advancements
Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia
Martin Tallman
In 2018, state-of-the-art treatment for acute myeloid leukemia (AML) is characterized by 6 features: Defined by cytogenetic and molecular interactions, Intensified induction/less intensive consolidation, Increased importance of minimal
Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers
Alison R. Walker and Guido Marcucci
For patients with acute myeloid leukemia (AML), acquired chromosomal abnormalities present at diagnosis are the most important independent predictors of complete remission, disease-free survival, and overall survival. 1 - 3 Chromosomal analysis
Acute Myeloid Leukemia: Selecting Induction Therapy Based on Biological Disease Factors
Presented by: Rebecca Olin
For patients with newly diagnosed acute myeloid leukemia (AML), leveraging cytogenetic, fluorescence in situ hybridization (FISH), and molecular genetic data plays a critical role in the selection of induction therapy. At the NCCN 2023 Annual
